Expert Interview
A third look: Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Ticker(s): CSL.XASXInstitution: Valley Children's Healthcare
- Board certified in pediatric hematology and oncology by the American Board of Pediatrics
- primary interests include the diagnosis, treatment, and care of children with various cancers and blood disorders with a special interest, unique expertise, and vast experience in managing children with bleeding and clotting disorders
- treats 50 patients with hemophilia B
- familiar with HEMGENIX or the HOPE-B trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
